Efficacy of Dalbavancin in Osteoarticular Infections Associated With Hip and Knee Replacements
Latest Information Update: 18 Mar 2024
At a glance
- Drugs Dalbavancin (Primary) ; Rifampicin (Primary)
- Indications Bone and joint infections; Osteomyelitis; Staphylococcal infections; Streptococcal infections
- Focus Therapeutic Use
- Acronyms PRO-DALBA
- 12 Mar 2024 Planned End Date changed from 29 Sep 2024 to 30 Sep 2024.
- 12 Mar 2024 Planned primary completion date changed from 29 Sep 2022 to 30 Sep 2024.
- 12 Mar 2024 Status changed from not yet recruiting to recruiting.